“We can’t take the orphan drug revolution for granted.“ Biorasi’s Few & Far Between Podcast welcomes Jim Geraghty, author and biotech industry veteran, to discuss the necessity and viability of orphan and rare disease research - for both patients and VC investors alike.
"It's amazing how many companies there are and how many opportunities for a kind of a match between a human that needs some help...
“Our studies are open for those that have exhausted standard of care, and we're showing improved responses, and the data is promising. So, I...
Social media platforms and podcasts are spotlighting the untold stories of rare disease patients and their families. Find out more in today's Few &...